The NICE has issued positive final draft guidance recommending Rinvoq (upadacitinib) as an additional treatment option for adults with moderately to severely active UC despite treatment with conventional or biologic therapies
The recommendation was based on the P-III (U-ACHIEVE) and (U-ACCOMPLISH) studies as induction therapy evaluating upadacitinib (45mg, qd) along with P-III (U-ACHIEVE) as maintenance therapy evaluating upadacitinib (15/30mg, qd)
In the induction trials, 26% and 33% of participants achieved the 1EPs of clinical remission @8wks. over 5% & 4% in both studies. In the maintenance trial, 42% & 52% achieved the 1EPs of clinical remission @52wks. over 12% who received PBO for both doses
Ref: PRNewswire | Image: CK Life Sciences
